Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities

BACKGROUND: Elderly patients (≥65 yr) with advanced prostate cancer and cardiovascular disease (CVD) conditions are often excluded from clinical trials of abiraterone acetate (AA) or enzalutamide (ENZ). Consequently, little is known about the effects of these medications on these vulnerable patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Urol
Main Authors: Lu-Yao, Grace, Nikita, Nikita, Keith, Scott W., Nightingale, Ginah, Gandhi, Krupa, Hegarty, Sarah E., Rebbeck, Timothy R., Chapman, Andrew, Kantoff, Philip W., Cullen, Jennifer, Gomella, Leonard, Kelly, William Kevin
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6980462/
https://ncbi.nlm.nih.gov/pubmed/31420248
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2019.07.031
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados